Minal A. Barve
Expertise in
15
conditions

Dr. Minal A. Barve

Oncology | Hematology | Internal Medicine
8196 Walnut Hill Ln, Ste 100, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Referral may be required
Expertise in
15
conditions
8196 Walnut Hill Ln, Ste 100, 
Dallas, TX 

Overview

Minal Barve is a Hematologist and an Oncologist practicing medicine in Dallas, Texas.

Dr. Barve is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Non-Hodgkin Lymphoma, Follicular Lymphoma, and Lung Cancer.

Dr. Barve is board certified in Medical Oncology- American Board Of Internal Medicine, Medical Oncology- American Board Of Internal Med/Medical Oncology, Internal Medicine- American Board Of Internal Med, and Internal Medicine- American Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 58 peer reviewed articles and participating in 37 clinical trials. Dr. Barve is currently accepting new patients.

Graduate Institution

Dr. Panjabrao Alias Bhausaheb Deshmukh Memorial Medical College - 1993|Texas Health Presbyterian Hospital Of Dallas - 1997|Baylor University Medical Center - 2003

Residency

Internal Medicine, Presbyterian Hospital of Dallas - 1999

Specialties

Oncology
Hematology
Internal Medicine

Licenses

Internal Medicine in TX

Board Certifications

Medical Oncology- American Board Of Internal Medicine
Medical Oncology- American Board Of Internal Med/Medical Oncology
Internal Medicine- American Board Of Internal Med
Internal Medicine- American Board Of Internal Medicine

Fellowships

Medical Oncology, Baylor University Hospital - 2003
Medical Oncology, Baylor University Medical Center - 2003

Hospital Affiliations

Texas Health Presbyterian Hospital Dallas

Languages Spoken

English
Hindi
Marathi

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Texas Oncology - Dallas
8196 Walnut Hill Ln, Ste 100, Dallas, TX 75231
Other Locations
Texas Oncology Presbyterian Cancer Center Dallas
8196 Walnut Hill Ln, Ste 100, Dallas, TX 75231
Texas Oncology, P.A.
8196 Walnut Hill Lane, Suite 100, Dallas, TX 75231

Additional Areas of Focus

Dr. Barve has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

37 Clinical Trials

Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study
Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Drug
Study Drugs: Dabrafenib, Trametinib
Study Phase: Phase 4
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors
An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2026
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
Enrollment Status: Completed
Publish Date: April 17, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
Enrollment Status: Completed
Publish Date: March 27, 2026
Intervention Type: Drug, Biological
Study Drugs: SV-BR-1-GM, INCMGA00012, Low Dose Cyclophosphamide, Interferon Inoculation, Epacadosta
Study Phase: Phase 1/Phase 2
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: January 27, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Rituximab
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects
A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Enrollment Status: Completed
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: INCAGN01876, Nivolumab, Ipilimumab
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

58 Total Publications

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.
Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: September 02, 2026
Similar Doctors
Expertise in
38
conditions
Dr. Farrukh T. Awan
Hematology | Oncology
Expertise in
38
conditions
Dr. Farrukh T. Awan
Hematology | Oncology
Referral may be required

UT Southwestern-Bill And Rita Clements Advanced Medical Imaging Center

2201 Inwood Rd, 
Dallas, TX 
 (6.4 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Farrukh Awan is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Awan is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
33
conditions
Dr. Daniel C. Bowers
Hematology | Oncology
Expertise in
33
conditions
Dr. Daniel C. Bowers
Hematology | Oncology
Referral may be required

Children's Medical Center/Children's Health

1935 Medical District Dr, 
Dallas, TX 
 (6.8 miles away)
214-456-2382
Languages Spoken:
English
See accepted insurances

Daniel Bowers is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Bowers is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Ependymoma, Posterior Fossa Tumor, Medulloblastoma, and Brain Tumor.

Expertise in
11
conditions
Dr. Naomi J. Winick
Hematology | Oncology
Expertise in
11
conditions
Dr. Naomi J. Winick
Hematology | Oncology
Referral may be required

Children's Medical Center/Children's Health

1935 Medical District Dr, 
Dallas, TX 
 (6.8 miles away)
214-648-3896
Languages Spoken:
English
See accepted insurances

Naomi Winick is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Winick is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Febrile Neutropenia, Childhood Acute Myeloid Leukemia, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Minal A. Barve

How do I make an appointment with Dr. Minal A. Barve?

You can book an appointment with Dr. Minal A. Barve by calling their office at 214-739-4175. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Minal A. Barve a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Minal A. Barve is classified as an Advanced expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Minal A. Barve specialize in?

While Dr. Minal A. Barve is a Oncology, they have specific expertise in Ovarian Cancer, Non-Hodgkin Lymphoma, and Follicular Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Minal A. Barve participate in research or clinical trials?

Yes. Dr. Minal A. Barve has published 58 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Minal A. Barve's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Minal A. Barve accept my insurance?

Dr. Minal A. Barve accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 214-739-4175 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Barve's expertise for a condition
ConditionClose
      View All 15 Advanced Conditions
      View All 83 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile